WO1996018372A3 - Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules - Google Patents

Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules Download PDF

Info

Publication number
WO1996018372A3
WO1996018372A3 PCT/US1995/016174 US9516174W WO9618372A3 WO 1996018372 A3 WO1996018372 A3 WO 1996018372A3 US 9516174 W US9516174 W US 9516174W WO 9618372 A3 WO9618372 A3 WO 9618372A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic
gene therapy
cationic
therapeutic compositions
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1995/016174
Other languages
French (fr)
Other versions
WO1996018372A2 (en
Inventor
Craig S Siegel
David J Harris
Edward R Lee
Shirley C Hubbard
Seng H Cheng
Simon J Eastman
John Marshall
Ronald K Scheule
Nelson S Yew
Mathieu B Lane
Eric A Rowe
Rebecca G Bagley
Chau-Dung Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27533061&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1996018372(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/352,479 external-priority patent/US5650096A/en
Priority claimed from US08/540,867 external-priority patent/US5747471A/en
Priority to JP8519236A priority Critical patent/JPH10510813A/en
Priority to EP95943769A priority patent/EP0799059B1/en
Priority to DK95943769T priority patent/DK0799059T3/en
Priority to AT95943769T priority patent/ATE221390T1/en
Application filed by Genzyme Corp filed Critical Genzyme Corp
Priority to DE69527650T priority patent/DE69527650T2/en
Priority to AU45161/96A priority patent/AU716706C/en
Publication of WO1996018372A2 publication Critical patent/WO1996018372A2/en
Publication of WO1996018372A3 publication Critical patent/WO1996018372A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or acyl groups; and cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile. Novel and highly effective plasmid constructs are also disclosed, including those that are particularly effective at providing gene therapy for clinical conditions complicated by inflammation. Additionally, targeting of organs for gene therapy by intravenous administration of therapeutic compositions is described.
PCT/US1995/016174 1994-12-09 1995-12-08 Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules Ceased WO1996018372A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU45161/96A AU716706C (en) 1994-12-09 1995-12-08 Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
DE69527650T DE69527650T2 (en) 1994-12-09 1995-12-08 CATONIC AMPHIPHILES AND PLASMIDES FOR THE INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS
JP8519236A JPH10510813A (en) 1994-12-09 1995-12-08 Cationic amphiphilic compounds and plasmids for intracellular delivery of therapeutic molecules
EP95943769A EP0799059B1 (en) 1994-12-09 1995-12-08 Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
DK95943769T DK0799059T3 (en) 1994-12-09 1995-12-08 Cationic amphiphilic compounds and plasmids for intracellular administration of therapeutic molecules
AT95943769T ATE221390T1 (en) 1994-12-09 1995-12-08 CATONIC AMPHIPHILES AND PLASMIDS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US08/352,479 US5650096A (en) 1994-12-09 1994-12-09 Cationic amphiphiles for intracellular delivery of therapeutic molecules
US434495P 1995-09-26 1995-09-26
US439995P 1995-09-27 1995-09-27
US08/540,867 US5747471A (en) 1994-12-09 1995-10-11 Cationic amphiphiles containing steroid lipophilic groups for intracellular delivery of therapeutic molecules
US08/545,473 US6071890A (en) 1994-12-09 1995-10-19 Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US60/004,344 1995-10-19
US08/540,867 1995-10-19
US60/004,399 1995-10-19
US08/545,473 1995-10-19
US08/352,479 1995-10-19

Publications (2)

Publication Number Publication Date
WO1996018372A2 WO1996018372A2 (en) 1996-06-20
WO1996018372A3 true WO1996018372A3 (en) 1996-09-06

Family

ID=27533061

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/016174 Ceased WO1996018372A2 (en) 1994-12-09 1995-12-08 Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules

Country Status (8)

Country Link
US (1) US6071890A (en)
EP (1) EP0799059B1 (en)
JP (1) JPH10510813A (en)
AT (1) ATE221390T1 (en)
DE (1) DE69527650T2 (en)
DK (1) DK0799059T3 (en)
PT (1) PT799059E (en)
WO (1) WO1996018372A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601872B2 (en) 1998-11-12 2009-10-13 Life Technologies Corporation Transfection reagents

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795870A (en) * 1991-12-13 1998-08-18 Trustees Of Princeton University Compositions and methods for cell transformation
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US6383814B1 (en) 1994-12-09 2002-05-07 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5948767A (en) * 1994-12-09 1999-09-07 Genzyme Corporation Cationic amphiphile/DNA complexes
US6331524B1 (en) 1994-12-09 2001-12-18 Genzyme Corporation Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy
US5939401A (en) * 1994-12-09 1999-08-17 Genzyme Corporation Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
US5962428A (en) * 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US6339173B1 (en) 1996-07-22 2002-01-15 Promega Biosciences, Inc. Amide-based cationic lipids
EP0779361A3 (en) 1995-12-15 1999-11-10 F. Hoffmann-La Roche Ag Truncated form of inhibitory kappa B protein (1kB), recombinant production and uses thereof
FR2744453B1 (en) * 1996-02-05 1998-07-10 Transgene Sa LIPOPOLYAMINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, NUCLEIC ACID TRANSFER VECTORS AND PREPARATION METHOD
DE19607686A1 (en) * 1996-02-29 1997-09-04 Chemicon Lab Gmbh New metabolizable lipopolyamines, their presentation and application
FR2751972B1 (en) * 1996-07-30 1998-09-04 Centre Nat Rech Scient COMPOUNDS RELATED TO THE AMIDINIUM FAMILY, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR APPLICATIONS
DE69703878T2 (en) * 1996-03-01 2001-04-26 Centre National De La Recherche Scientifique (C.N.R.S.), Paris GUANIDINIUM COMPOUNDS, PHARMACEUTICAL PREPARATIONS THEREOF AND THEIR USE
US6258792B1 (en) 1996-04-12 2001-07-10 University Of Pittsburgh Cationic cholesteryl derivatives containing cyclic polar groups
DK0904282T3 (en) 1996-04-12 2002-03-04 Univ Pittsburgh Novel cationic cholesteryl derivatives containing cyclic polar groups
AU2911197A (en) * 1996-05-24 1998-01-05 Imperial College Of Science, Technology And Medicine Polycationic sterol derivatives as transfection agents
US5935936A (en) * 1996-06-03 1999-08-10 Genzyme Corporation Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules
US6093816A (en) 1996-06-27 2000-07-25 Isis Pharmaceuticals, Inc. Cationic lipids
DE19631189A1 (en) * 1996-08-02 1998-02-05 Max Delbrueck Centrum Novel cationic amphiphiles for liposomal gene transfer
US6251433B1 (en) 1996-08-13 2001-06-26 Chiron Corporation Polycationic polymers
US5962429A (en) * 1996-11-22 1999-10-05 University Of Iowa Complexes of adenovirus with cationic molecules
IL131328A0 (en) * 1997-02-28 2001-01-28 Boehringer Ingelhem Pharmaceut Self-regulated apoptosis of inflammatory cells by gene therapy
US5837283A (en) * 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US5925628A (en) * 1997-03-31 1999-07-20 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5912239A (en) * 1997-04-04 1999-06-15 Genzyme Corporation Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules
US6020191A (en) * 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US5981275A (en) * 1997-04-14 1999-11-09 Genzyme Corporation Transgene expression system for increased persistence
US5948925A (en) * 1997-05-06 1999-09-07 Genzyme Corporation Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids
US5952516A (en) * 1997-05-08 1999-09-14 Genzyme Corporation Cationic amphiphiles containing multiplesteroid lipophilic groups
US5942634A (en) * 1997-05-09 1999-08-24 Genzyme Corporation Cationic amphiphiles for cell transfections
US6835395B1 (en) 1997-05-14 2004-12-28 The University Of British Columbia Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
WO1998051278A2 (en) 1997-05-14 1998-11-19 Inex Pharmaceuticals Corporation High efficiency encapsulation of charged therapeutic agents in lipid vesicles
WO1998051285A2 (en) * 1997-05-15 1998-11-19 Genzyme Corporation Cationic amphiphile formulations
FR2765877B1 (en) * 1997-07-10 1999-09-10 Oreal COMPOSITION COMPRISING AN AQUEOUS DISPERSION OF LIPID VESICLES BASED ON CHOLESTERYL CHAIN CARBAMATES, USE IN PARTICULAR IN COSMETICS AND NEW COMPOUNDS
WO1999002190A1 (en) * 1997-07-11 1999-01-21 Genzyme Corporation Organ-specific targeting of cationic amphiphile/retinoblastoma encoding dna complexes for gene therapy
US6197332B1 (en) 1997-08-13 2001-03-06 Chiron Corporation Lipid-conjugated polyamide compounds and related compositions and methods thereof
CA2299429C (en) 1997-08-13 2010-04-20 Biontex Laboratories Gmbh New lipopolyamines,their preparation and the use thereof
US6066626A (en) 1997-10-29 2000-05-23 Genzyme Corporation Compositions and method for treating lysosomal storage disease
CA2309766C (en) 1997-11-20 2008-09-30 Vical Incorporated Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor
EP1089757B1 (en) 1998-06-17 2009-04-22 IDM Pharma, Inc. Hla binding peptides and their uses
WO2000011019A1 (en) 1998-08-21 2000-03-02 Felix Frey Conjugates of dna interacting groups with steroid hormones for use as nucleic acid transfection agent
DE19956568A1 (en) * 1999-01-30 2000-08-17 Roland Kreutzer Method and medicament for inhibiting the expression of a given gene
DK1059092T3 (en) * 1999-06-08 2006-03-27 Gentium Spa Use of complexes of cationic liposomes and polydeoxyribonucleotides as drugs
DE19944262A1 (en) * 1999-09-15 2001-03-29 Cardiogene Gentherapeutische S Pharmaceutical composition in the form of a nucleic acid-lipid complex, its production and use in gene therapy
US7829693B2 (en) * 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
AU2637500A (en) * 1999-12-10 2001-06-18 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
GB0015624D0 (en) * 2000-06-26 2000-08-16 Nat Cancer Centre Materials and methods relating to improved gene delivery
ATE429643T1 (en) 2000-07-12 2009-05-15 Agensys Inc NEW TUMOR ANTIGEN THAT CAN BE USED FOR DIAGNOSIS AND THERAPY OF BLADDER, OVARY, LUNG AND KIDNEY CANCER
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
WO2002072790A2 (en) 2001-03-14 2002-09-19 Myriad Genetics, Inc Tsg101-gag interaction and use thereof
US7294511B2 (en) * 2001-03-22 2007-11-13 Chromos Molecular Systems, Inc. Methods for delivering nucleic acid molecules into cells and assessment thereof
US20030185870A1 (en) * 2001-11-20 2003-10-02 Grinstaff Mark W. Interfacial biomaterials
EP1572933A4 (en) 2002-02-13 2007-09-05 Univ Duke MODULATION OF IMMUNE RESPONSE BY POLYPEPTIDES OF RESPONSE TO STRESS BINDING TO NON PEPTIDES
SI2332582T1 (en) * 2002-06-19 2014-03-31 Apeiron Biologics Ag ACE2 activation for treatment of heart, lung and kidney disease and hypertension
US20060079453A1 (en) 2002-10-03 2006-04-13 John Sidney Hla binding peptides and their uses
WO2004100890A2 (en) * 2003-05-09 2004-11-25 The Trustees Of Columbia University In The City Of New York Rage g82s-related methods and compositions for treating inflammatory disorders
AU2004246904B2 (en) * 2003-06-18 2010-02-04 Biolab Ltd. Sphingolipids polyalkylamine conjugates for use in transfection
US7608699B2 (en) 2003-12-29 2009-10-27 Rockefeller University Synthetic nuclear localization signal derived from lentiviral integrase and methods of use thereof
CA2564616C (en) * 2004-04-20 2016-08-30 Nastech Pharmaceutical Company Inc. Methods and compositions for enhancing delivery of double-stranded rna or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells
EP1793875B9 (en) 2004-06-16 2010-09-08 Affinergy, Inc. Ifbm's to promote attachment of target analytes
JP2009501002A (en) 2005-06-07 2009-01-15 ザ ロックフェラー ユニバーシティ Method for stimulating pancreatic beta cell proliferation
JP5405824B2 (en) 2005-06-30 2014-02-05 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ Progenitor cells and uses thereof
CA2633065C (en) 2005-12-15 2016-10-18 Centre National De La Recherche Scientifique (Cnrs) Cationic oligonucleotides, automated methods for preparing same and their uses
US7807624B2 (en) * 2006-01-11 2010-10-05 Affinergy, Inc. Methods and compositions for promoting attachment of cells of endothelial cell lineage to medical devices
EP1844772A1 (en) * 2006-04-06 2007-10-17 Polyplus-Transfection SA Compositions for transfection of oligonucleotides active for gene silencing and their biological and therapeutical applications
WO2007150069A2 (en) 2006-06-23 2007-12-27 Myriad Genetics, Inc. Dpyd gene variants and use thereof
CN102978185B (en) 2007-01-18 2015-02-11 建新公司 Oligosaccharides comprising an aminooxy group and conjugates thereof
EP2215111B1 (en) 2007-11-01 2016-03-16 Mayo Foundation For Medical Education And Research Hla-dr binding peptides and their uses
FR2925491B1 (en) * 2007-12-19 2010-09-03 Oz Biosciences Sas NEW CLASSES OF CATIONIC LIPIDS FOR THE TRANSPORT OF ACTIVE AGENTS IN CELLS
EP2077119A1 (en) * 2007-12-21 2009-07-08 Apeiron Biologics Forschungs- und Entwicklungsgesellschaft M.B.H. Treatment of fibrosis and liver diseases
FR2926818B1 (en) * 2008-01-30 2012-04-06 Centre Nat Rech Scient CATIONIC siRNA, SYNTHESIS AND USE FOR RNA INTERFERENCE
EP2123256A1 (en) 2008-05-19 2009-11-25 Ruhr-Universität Bochum Perfluorcarbon nanoemulsions with endocytosis enhancing surface for gene-transfer
US20110200525A1 (en) * 2008-10-09 2011-08-18 Patz Jr Edward F Vhh antibody fragments for use in the detection and treatment of cancer
JP2012509272A (en) * 2008-11-17 2012-04-19 エンゾン ファーマシューティカルズ，インコーポレーテッド Releasable cationic lipids for nucleic acid delivery systems
PL2889043T3 (en) 2008-12-16 2019-09-30 Genzyme Corporation Synthetic intermediates for preparing oligosaccharide-protein conjugates
EP2451475A2 (en) 2009-07-06 2012-05-16 Novartis AG Self replicating rna molecules and uses thereof
TW201116294A (en) 2009-07-15 2011-05-16 Novartis Ag RSV F protein compositions and methods for making same
US8518405B2 (en) 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
PL3338765T3 (en) 2009-12-01 2019-06-28 Translate Bio, Inc. Steroid derivative for the delivery of mrna in human genetic diseases
KR102095670B1 (en) 2010-05-14 2020-03-31 더 제너럴 하스피톨 코포레이션 Compositions and methods of identifying tumor specific neoantigens
EP3520813B1 (en) 2010-10-11 2023-04-19 GlaxoSmithKline Biologicals S.A. Antigen delivery platforms
US9011292B2 (en) 2010-11-01 2015-04-21 Nike, Inc. Wearable device assembly having athletic functionality
JP2014508102A (en) 2010-11-15 2014-04-03 ライフ テクノロジーズ コーポレーション Amine-containing transfection reagents and methods for producing and using the same
ES2644236T3 (en) 2010-12-14 2017-11-28 National University Of Singapore Monoclonal human antibody with specificity for Dengue serotype 1 E protein and its uses
EP4144368B1 (en) 2011-01-26 2025-02-26 GlaxoSmithKline Biologicals S.A. Rsv immunization regimen
RU2013151875A (en) 2011-04-22 2015-05-27 Джензим Корпорейшн MODIFIED ACID ALPHA GLUCOSIDASE WITH ACCELERATED PROCESSING
CN103842374A (en) 2011-05-13 2014-06-04 诺华股份有限公司 Pre-fusion rsv f antigens
PT2717893T (en) 2011-06-08 2019-08-20 Translate Bio Inc Lipid nanoparticle compositions and methods for mrna delivery
EP3854413A1 (en) 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
CA2841047A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
US20140271829A1 (en) 2011-10-11 2014-09-18 Anders Lilja Recombinant self-replicating polycistronic rna molecules
EP2766385A2 (en) 2011-10-12 2014-08-20 Novartis AG Cmv antigens and uses thereof
EP2785370B1 (en) 2011-12-02 2021-07-21 Rhode Island Hospital Vaccine for falciparum malaria
WO2013185067A1 (en) 2012-06-08 2013-12-12 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
US20150140068A1 (en) 2012-07-06 2015-05-21 Novartis Ag Immunogenic compositions and uses thereof
CN104981249B (en) * 2012-12-18 2018-06-19 英国卫生部 Antimicrobe compound, their synthesis and its application
WO2014108515A1 (en) 2013-01-10 2014-07-17 Novartis Ag Influenza virus immunogenic compositions and uses thereof
EP2968586B1 (en) 2013-03-14 2018-07-25 Translate Bio, Inc. Cftr mrna compositions and related methods and uses
ES2981185T3 (en) 2013-03-14 2024-10-07 Translate Bio Inc Methods for purifying messenger RNA
BR112015025460B1 (en) 2013-04-07 2024-01-02 The Broad Institute, Inc. METHOD FOR PRODUCING A PERSONALIZED VACCINE AGAINST NEOPLASM FOR AN INDIVIDUAL DIAGNOSED AS HAVING A NEOPLASM, PERSONALIZED VACCINE AND USE THEREOF
MX2016005239A (en) 2013-10-22 2016-08-12 Shire Human Genetic Therapies TREATMENT WITH MESSENGER RIBONUCLEIC ACID FOR PHENYLKETONURIA.
US11224642B2 (en) 2013-10-22 2022-01-18 Translate Bio, Inc. MRNA therapy for argininosuccinate synthetase deficiency
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
NZ721908A (en) 2013-12-20 2022-12-23 Massachusetts Gen Hospital Combination therapy with neoantigen vaccine
JP6571679B2 (en) 2014-04-25 2019-09-04 トランスレイト バイオ， インコーポレイテッド Method for purifying messenger RNA
WO2016011203A1 (en) 2014-07-15 2016-01-21 Life Technologies Corporation Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
ES2830392T3 (en) 2014-07-23 2021-06-03 Ohio State Innovation Foundation Methods and compositions related to antibody fragments that bind to tumor-associated glycoprotein 72 (TAG-72)
EP3031822A1 (en) 2014-12-08 2016-06-15 Novartis AG Cytomegalovirus antigens
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
EP4636401A2 (en) 2014-12-19 2025-10-22 The Broad Institute, Inc. Methods for profiling the t-cell-receptor repertoire
EP3047856A1 (en) 2015-01-23 2016-07-27 Novartis AG Cmv antigens and uses thereof
CA2986235A1 (en) 2015-05-20 2016-11-24 The Broad Institute, Inc. Shared neoantigens
TWI750122B (en) 2015-06-09 2021-12-21 美商博德研究所有限公司 Formulations for neoplasia vaccines and methods of preparing thereof
WO2017044866A2 (en) 2015-09-11 2017-03-16 Nascent Biotech, Inc. Enhanced delivery of drugs to the brain
KR102883915B1 (en) 2015-12-16 2025-11-18 시애틀 프로젝트 코포레이션 Identification, production, and use of neoantigens
CR20180519A (en) 2016-03-31 2019-03-05 Neon Therapeutics Inc NEOANT US AND METHODS OF USE
AU2017254477A1 (en) 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
AU2018224326B2 (en) 2017-02-27 2024-01-04 Translate Bio, Inc. Novel codon-optimized CFTR mRNA
JP7457642B2 (en) 2017-04-03 2024-03-28 ビオンテック ユーエス インコーポレイテッド Protein antigens and uses thereof
CN106995384B (en) * 2017-04-21 2018-12-11 郑州大学 Amphipathic antibacterial peptide mimics of dialkyl cationic with antibacterial activity and preparation method thereof
MX2019013752A (en) 2017-05-16 2020-07-20 Translate Bio Inc Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr.
WO2018213803A1 (en) 2017-05-19 2018-11-22 Neon Therapeutics, Inc. Immunogenic neoantigen identification
WO2019075112A1 (en) 2017-10-10 2019-04-18 Gritstone Oncology, Inc. Neoantigen identification using hotspots
KR20260008173A (en) 2017-11-22 2026-01-15 시애틀 프로젝트 코포레이션 Reducing junction epitope presentation for neoantigens
JP7653013B2 (en) 2018-01-04 2025-03-28 アイコニック セラピューティクス リミテッド ライアビリティ カンパニー Anti-Tissue Factor Antibodies, Antibody Drug Conjugates, and Related Methods
US11547666B2 (en) * 2018-05-30 2023-01-10 Translate Bio, Inc. Cationic lipids comprising a steroidal moiety
CN118421617A (en) 2018-08-24 2024-08-02 川斯勒佰尔公司 Method for purifying messenger RNA
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
EP3883592A1 (en) 2018-11-21 2021-09-29 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of nebulized mrna encoding cftr
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
US12419949B2 (en) 2019-07-24 2025-09-23 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
US12622926B2 (en) 2019-09-02 2026-05-12 Institut Curie Immunotherapy targeting tumor neoantigenic peptides
WO2021055609A1 (en) 2019-09-20 2021-03-25 Translate Bio, Inc. Mrna encoding engineered cftr
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
WO2021078910A1 (en) 2019-10-22 2021-04-29 Institut Curie Immunotherapy targeting tumor neoantigenic peptides
CA3173793A1 (en) 2020-04-03 2021-10-07 Andrew Ferguson Infectious disease antigens and vaccines
US20230212243A1 (en) 2020-05-12 2023-07-06 Institut Curie Neoantigenic Epitopes Associated with SF3B1 Mutations
US12030912B2 (en) * 2020-05-15 2024-07-09 Brigham Young University Cationic steroidal antimicrobial compounds with urethane linkages
JP2023538260A (en) * 2020-08-06 2023-09-07 モダーナティエックス・インコーポレイテッド Compositions for delivering payload molecules to airway epithelium
CA3202176A1 (en) 2020-12-14 2022-06-23 Michael Steven ROONEY Tissue-specific antigens for cancer immunotherapy
WO2022155500A1 (en) 2021-01-14 2022-07-21 Senti Biosciences, Inc. Secretable payload regulation
KR20230172630A (en) 2021-03-11 2023-12-22 므네모 테라퓨틱스 Tumor Neoantigenic Peptide
CA3213002A1 (en) 2021-03-11 2022-09-15 Institut Curie Transmembrane neoantigenic peptides
WO2023076598A1 (en) * 2021-10-29 2023-05-04 Modernatx, Inc. Lipid amines
EP4469078A1 (en) 2022-01-28 2024-12-04 GlaxoSmithKline Biologicals S.A. Modified human cytomegalovirus proteins
CA3254182A1 (en) 2022-03-24 2023-09-28 Universite Paris Cite Immunotherapy targeting tumor transposable element derived neoantigenic peptides in glioblastoma
CN117003808A (en) * 2022-04-28 2023-11-07 北京科兴中维生物技术有限公司 A cationic lipid compound and its preparation method and use
US12084703B2 (en) 2022-05-12 2024-09-10 SunVax mRNA Therapeutics Inc. Synthetic self-amplifying mRNA molecules with secretion antigen and immunomodulator
EP4721759A1 (en) * 2023-04-29 2026-04-08 Cansino (Shanghai) Biological Research Co., Ltd. Lipid nanoparticle for delivering nucleic acid drug, and preparation method therefor and use thereof
AU2024344227A1 (en) 2023-09-19 2026-04-30 Regeneron Pharmaceuticals, Inc. Viral peptides and uses thereof
WO2025136809A2 (en) 2023-12-19 2025-06-26 Regeneron Pharmaceuticals, Inc. Foxp3 peptides and uses thereof
WO2025178991A1 (en) 2024-02-21 2025-08-28 Regeneron Pharmaceuticals, Inc. Splicing factor gene mutation-associated neoantigenic peptides and uses thereof
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof
EP4702988A1 (en) 2024-08-28 2026-03-04 Biotechnology Assets S.A. Combination product for the treatment of leishmaniasis
WO2026062222A1 (en) 2024-09-20 2026-03-26 Institut Curie Novel protein isoforms and uses
WO2026090560A1 (en) 2024-10-25 2026-04-30 Crank Bio, Inc. Engineered nucleic acids and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988000824A1 (en) * 1986-07-28 1988-02-11 Liposome Technology, Inc. Liposomes with enhanced retention on mucosal tissue
US4971803A (en) * 1985-04-08 1990-11-20 California Institute Of Technology Lamellar vesicles formed of cholesterol derivatives
US5004737A (en) * 1989-09-22 1991-04-02 Pacific Chemical Co., Ltd. Quaternary ammonium-substituted sterol derivatives
EP0490379A2 (en) * 1990-12-13 1992-06-17 BERLIN-CHEMIE Aktiengesellschaft Diamino acid derivatives and pharmaceutical compositions
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
WO1994005624A1 (en) * 1992-08-28 1994-03-17 Life Technologies, Inc. Cationic lipids
WO1994020520A1 (en) * 1993-03-10 1994-09-15 Magainin Pharmaceuticals Inc. Steroid derivatives, pharmaceutical compositions containing them, and their use as antibiotics or disinfectants

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
FR2645866B1 (en) * 1989-04-17 1991-07-05 Centre Nat Rech Scient NEW LIPOPOLYAMINES, THEIR PREPARATION AND THEIR USE
US4958013A (en) * 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5908635A (en) * 1994-08-05 1999-06-01 The United States Of America As Represented By The Department Of Health And Human Services Method for the liposomal delivery of nucleic acids
US5837533A (en) * 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
DE59507224D1 (en) * 1994-12-28 1999-12-16 Max Delbrueck Centrum New cholesterol derivative for liposomal gene transfer

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4971803A (en) * 1985-04-08 1990-11-20 California Institute Of Technology Lamellar vesicles formed of cholesterol derivatives
WO1988000824A1 (en) * 1986-07-28 1988-02-11 Liposome Technology, Inc. Liposomes with enhanced retention on mucosal tissue
US5004737A (en) * 1989-09-22 1991-04-02 Pacific Chemical Co., Ltd. Quaternary ammonium-substituted sterol derivatives
EP0490379A2 (en) * 1990-12-13 1992-06-17 BERLIN-CHEMIE Aktiengesellschaft Diamino acid derivatives and pharmaceutical compositions
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
WO1994005624A1 (en) * 1992-08-28 1994-03-17 Life Technologies, Inc. Cationic lipids
WO1994020520A1 (en) * 1993-03-10 1994-09-15 Magainin Pharmaceuticals Inc. Steroid derivatives, pharmaceutical compositions containing them, and their use as antibiotics or disinfectants

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
K. R. PATEL ET AL: "Modification of vesicle surfaces with amphiphilic sterols. Effect on permeability and in vivo tissue distribution.", BIOCHIMICA ET BIOPHYSICA ACTA. BIOMEMBRANES, vol. 814, no. 2, 11 April 1985 (1985-04-11), pages 256 - 264, XP000573084 *
K. S. MOORE ET AL: "Squalamine: an aminosterol antibiotic from the shark.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 90, no. 4, February 1993 (1993-02-01), WASHINGTON US, pages 1354 - 1358, XP000572356 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601872B2 (en) 1998-11-12 2009-10-13 Life Technologies Corporation Transfection reagents
US9358300B2 (en) 1998-11-12 2016-06-07 Life Technologies Corporation Transfection reagents

Also Published As

Publication number Publication date
AU716706B2 (en) 2000-03-02
US6071890A (en) 2000-06-06
DE69527650D1 (en) 2002-09-05
AU4516196A (en) 1996-07-03
EP0799059A1 (en) 1997-10-08
ATE221390T1 (en) 2002-08-15
DE69527650T2 (en) 2003-02-27
DK0799059T3 (en) 2002-11-25
EP0799059B1 (en) 2002-07-31
WO1996018372A2 (en) 1996-06-20
PT799059E (en) 2002-11-29
JPH10510813A (en) 1998-10-20

Similar Documents

Publication Publication Date Title
WO1998002190A3 (en) Cationic amphiphile/dna complexes
PT799059E (en) CATIONIC AND PLASMIDE ANATYFILS FOR INTRACELLULAR ADMINISTRATION OF THERAPEUTIC MOLECULES
DE69832293T2 (en) PREPARATIONS FOR THE DELIVERY OF NEGATIVELY LOADED MOLECULES
CA2270396C (en) Cationic reagents for transfection
US6858225B2 (en) Lipid-encapsulated polyanionic nucleic acid
JP6126072B2 (en) Processes and compositions for efficient delivery by liposomes in therapy to suppress gene expression
JP5042863B2 (en) Lipid nanoparticle-based compositions and methods for delivering biologically active molecules
DE69736385T2 (en) CATIONIC LIPID AND RECEPTOR LIGAND FACILITATED GIVING OF BIOLOGICALLY ACTIVE MOLECULES
US20060147514A1 (en) Method for introducing antisense oligonucleotides into eucaryotic cells
JP2007505954A5 (en)
DE69636032D1 (en) PLASMIDE FOR THE ADMINISTRATION OF NUCLEIC ACIDS AND METHOD OF USE
Gruneich et al. Cationic corticosteroid for nonviral gene delivery
AU2008230379B2 (en) Prompt nucleic acid delivery carrier composition
AU2008325504B2 (en) Nucleic acid complex and nucleic acid delivery composition
AU751969B2 (en) Stabilization of lipid:DNA formulations during nebulization
KR100448298B1 (en) Glucocotricoid enhancement of gene expression
Walker et al. Chemistry and cellular aspects of cationic facial amphiphiles
Huang et al. Endosomolytic activity of cationic liposomes enhances the delivery of human immunodeficiency virus-1 trans-activator protein (TAT) to mammalian cells
WO2001042424A3 (en) Sphingolipid-containing cationic liposomes for topical delivery of bioactive material
DE10037861A1 (en) Composition for treating malignant disease, useful especially for cervical carcinoma, contains agent that inhibits activity of nucleolin
EP1724254A2 (en) Novel compositions for the delivery of negatively charged molecules
HK1029578B (en) Novel compositions for the delivery of negatively charged molecules
WO2009063081A2 (en) Composition comprising at least one nucleosidic moiety as a therapeutic agent, and ckc.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1995943769

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2205968

Country of ref document: CA

Ref country code: CA

Ref document number: 2205968

Kind code of ref document: A

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1995943769

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1995943769

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995943769

Country of ref document: EP